0001104659-21-089437.txt : 20210706
0001104659-21-089437.hdr.sgml : 20210706
20210706162739
ACCESSION NUMBER: 0001104659-21-089437
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210701
FILED AS OF DATE: 20210706
DATE AS OF CHANGE: 20210706
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Katabi Maha
CENTRAL INDEX KEY: 0001720685
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40544
FILM NUMBER: 211074427
MAIL ADDRESS:
STREET 1: SOFINNOVA INVESTMENTS
STREET 2: 3000 SAND HILL ROAD, 4-250
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc.
CENTRAL INDEX KEY: 0001798749
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831377888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: FLOOR 18
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 617-443-2400
MAIL ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: FLOOR 18
CITY: BOSTON
STATE: MA
ZIP: 02116
4
1
tm2121485-3_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-07-01
0
0001798749
Aerovate Therapeutics, Inc.
AVTE
0001720685
Katabi Maha
C/O AEROVATE THERAPEUTICS, INC.
200 BERKELEY STREET, FLOOR 18
BOSTON
MA
02116
1
0
1
0
Common Stock
2021-07-02
4
C
0
3401544
A
3401544
I
By Sofinnova Venture Partners X, L.P.
Common Stock
2021-07-02
4
P
0
357142
14
A
3758686
I
By Sofinnova Venture Partners X, L.P.
Stock Option (Right to Buy)
19.41
2021-07-01
4
A
0
2467
11.147
A
2031-06-30
Common Stock
2467
2467
D
Series A Preferred Stock
2021-07-02
4
C
0
10565238
D
Common Stock
3401544
0
I
By Sofinnova Venture Parnters X, L.P.
Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his or her proportionate pecuniary interest therein.
This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in two equal installments, with the first installment vesting on September 30, 2021 and the second installment vesting on December 31, 2021.
/s/ George A. Eldridge, Attorney-in-Fact
2021-07-06